Conference report: Long-term data from KarMMa study continue to demonstrate deep and durable responses with idecabtagene vicleucel in relapsed or refractory multiple myeloma (MM)

With a median follow-up of 24.8 months in 128 patients, representing longest follow-up to date from trial of a CAR T cell therapy in MM, overall response rate remained consistent, with 73% achieving partial response or better and 33% a complete response or better.

Source:

Biospace Inc.